TrialAnnals of the rheumatic diseases2015

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.

Tobias Alexander et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.